HIV self-testing (HIVST) was endorsed by WHO in 2016 as a strategy to reach individuals unable or unwilling to test through conventional facility-based services. Despite an estimated need of 177–192 million tests annually across low- and middle-income countries, confirmed global procurement reached only approximately 21 million kits over 2020–2023. This Policy Forum article argues that three interlocking structural failures explain this missed opportunity: research capture through demonstration projects that substituted for population-scale deployment; the supervised self-testing paradox, in which provider-assisted delivery reconstituted the clinic barriers HIVST was designed to bypass; and procurement conservatism that suppressed market development throughout the period. An analysis of national HIVST policy adoption across the 15 highest-burden African countries finds a mean adoption lag of 5.3 years after WHO endorsement and substantial heterogeneity in distribution model permissiveness, with no country specifying a minimum kit volume, coverage target, or accountability mechanism. These programmatic failures were compounded by the absence of any publicly accessible Africa-level HIVST volume series, making the scale of the missed opportunity impossible to measure from published data alone. The article calls for mandatory disaggregated commodity reporting, a binding Africa-specific distribution target of at least 50 million kits per year, community-based distribution as the default model, and explicit HIVST volume commitments in the 2026–2030 PEPFAR memoranda of understanding.
No takes yet. Share an insight, caveat, or question.
Granich et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: